澳洋健康(002172) - 2024 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2024 was ¥469,718,772.02, a decrease of 16.12% compared to ¥559,970,261.09 in the same period last year[2] - Net profit attributable to shareholders for Q3 2024 was ¥1,350,111.61, down 67.84% from ¥4,202,063.52 year-on-year[2] - The basic earnings per share for Q3 2024 was ¥0.0018, a decline of 67.27% compared to ¥0.0055 in the same period last year[2] - Total operating revenue for the current period is $1,501,392,158.94, a decrease of 7.5% from $1,623,745,504.62 in the previous period[13] - Net profit for the current period is $39,622,828.72, slightly down by 0.7% from $39,898,732.72 in the previous period[13] Cash Flow - The net cash flow from operating activities for the year-to-date was -¥229,235,524.51, a decrease of 23.89% compared to -¥185,029,234.52 in the previous year[2] - Cash inflow from operating activities increased to $1,762,781,352.49, up 7.1% from $1,646,450,086.07 in the previous period[15] - Net cash flow from financing activities decreased by 35.22% compared to the same period last year, as the decline in cash paid for financing activities exceeded the decrease in cash received[9] - Cash paid for other operating activities was 200,691,363.19 CNY, down from 246,981,929.68 CNY, a decrease of about 18.7%[16] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,932,468,426.22, down 13.78% from ¥2,241,371,837.83 at the end of the previous year[3] - Total liabilities decreased from CNY 2,166,565,617.51 to CNY 1,818,939,377.18, a reduction of around 16%[11] - Current assets decreased from CNY 1,320,065,483.65 to CNY 1,030,035,440.89, a decline of about 22%[11] Equity - The equity attributable to shareholders increased by 41.20% to ¥132,555,288.39 from ¥93,877,216.04 year-on-year[3] - The company's total equity increased from CNY 74,806,220.32 to CNY 113,529,049.04, an increase of approximately 51.7%[12] Investments - Long-term equity investments increased by 3602.41% compared to the beginning of the period, attributed to additional investments in joint ventures[8] - The company's long-term equity investments increased significantly from CNY 386,950.60 to CNY 14,326,493.92, a substantial increase of over 3700%[11] - Cash inflow from investment activities decreased by 99.90% compared to the same period last year, primarily due to a reduction in fixed asset disposals and no occurrence of subsidiary equity disposals[8] Expenses - Research and development expenses decreased by 100.00% compared to the same period last year, as no R&D expenses were incurred during the period[8] - Financial expenses decreased by 40.82% compared to the same period last year, due to increased interest income from matured time deposits used for guarantees[8] - Sales expenses decreased to $32,167,433.29, down 12.5% from $36,789,275.31 in the previous period[13] - Management expenses decreased to $92,868,985.94, down 4.0% from $97,560,377.11 in the previous period[13] Government Support - The company received government subsidies amounting to ¥593,092.25 during the reporting period, contributing positively to the financial results[6] Non-recurring Items - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 277.78% to ¥1,442,301.72 from ¥385,527.75 in the previous year[2] - Non-recurring losses totaled -¥92,190.11 for the reporting period, with a year-to-date total of ¥2,848,614.89[6]